Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7267
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection | |
Anu Haveri Nina Ekstrom Anna Solastie Camilla Virta Pamela Österlund Elina Isosaari Hanna Nohynek Arto Palmu Merit Melin | |
Acceso Abierto | |
Atribución-NoComercial-SinDerivadas | |
https://doi.org/10.1101/2021.07.13.21260426 | |
https://www.medrxiv.org/content/10.1101/2021.07.13.21260426v1 | |
Understanding for how long antibodies persist following Severe acute respiratory coronavirus 2 (SARS-CoV-2) infection provides important insight into estimating the duration of immunity induced by infection. We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and twelve months after diagnosis in 367 individuals of whom 13% had severe disease requiring hospitalization. We determined the SARS-CoV-2 spike (S-IgG) and nucleoprotein IgG concentrations and the proportion of subjects with neutralizing antibodies (NAb). We also measured the NAb titers among a smaller subset of participants (n=78) against a wild-type virus (B.1) and three variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2). We found that NAb against the wild-type virus and S-IgG persisted in 89% and 97% of subjects for at least twelve months after infection, respectively. IgG and NAb levels were higher after severe infection. NAb titers were significantly lower against variants compared to the wild-type virus. | |
medRxiv | |
13-07-2021 | |
Preimpreso | |
www.medrxiv.org | |
Inglés | |
Epidemia COVID-19 | |
Público en general | |
VIRUS RESPIRATORIOS | |
Versión publicada | |
publishedVersion - Versión publicada | |
Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
Fichero | Tamaño | Formato | |
---|---|---|---|
Persistence of neutralizing antibodies a year after SARS COV2 infection.pdf | 789.11 kB | Adobe PDF | Visualizar/Abrir |